Ionis Pharmaceuticals Inc. (IONS) has sought FDA approval to expand the label of Olezarsen to include the indication of severe hypertriglyceridemia (sHTG), and a decision is anticipated on June 30, 2026.Severe hypertriglyceridemia (sHTG) is a condition where the triglyceride level in the blood is 500 milligrams per deciliter (500 mg/dL) or more. It is associated with an increased risk of acute pancreatitis and other serious health complications. In clinical studies, Olezarsen demonstrated a highly statistically significant placebo-adjusted reduction in triglyceride levels of up to 72% and an 85% reduction in acute pancreatitis events with favorable safety and tolerability. Additionally, nearly 90% of Olezarsen-treated patients achieved triglyceride levels less than 500 mg/dL, which is below the risk threshold for acute pancreatitis, according to the company. Olezarsen is already approved by the FDA as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). The drug, marketed under the brand name Tryngolza, generated U.S. net product sales of $27 million in Q1, 2026, compared to $6 million in the year-ago quarter.IONS closed Tuesday’s (June 2, 2026) trading at $72.97, down 3.20%.